Cargando…
Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
Autores principales: | Lally, David R., Loewenstein, Anat, Arnold, Jennifer J., Yang, Yit C., Gedif, Kinfemichael, Best, Catherine, Patel, Hersh, Tadayoni, Ramin, Heier, Jeffrey S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219932/ https://www.ncbi.nlm.nih.gov/pubmed/35676464 http://dx.doi.org/10.1038/s41433-022-02130-2 |
Ejemplares similares
-
Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
por: Lally, David R., et al.
Publicado: (2022) -
Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
por: Tadayoni, Ramin, et al.
Publicado: (2023) -
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022) -
Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020) -
Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis
por: Schmidt-Erfurth, Ursula, et al.
Publicado: (2022)